Trial reportThe Journal of biological chemistry2015
Structural Basis for Clonal Diversity of the Public T Cell Response to a Dominant Human Cytomegalovirus Epitope.
Trial report in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- T cell receptor specificity landscape revealed through de novo peptide design.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Identification of antigen-specific functional CD8iScience · 2025Article
- T-cell receptor specificity landscape revealed through de novo peptide design.bioRxiv : the preprint server for biology · 2025Article
- Article
- AI/ML-empowered approaches for predicting T Cell-mediated immunity and beyond.Frontiers in immunology · 2025Article
- Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy.Experimental hematology & oncology · 2024Review
- Antigen identification and high-throughput interaction mapping by reprogramming viral entry.Nature methods · 2022Article
- T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components.JCI insight · 2022Article
- CD8Science immunology · 2021Article
- Characterization of amino acid residues of T-cell receptors interacting with HLA-A*02-restricted antigen peptides.Annals of translational medicine · 2021Article
- Antigen identification for HLA class I- and HLA class II-restricted T cell receptors using cytokine-capturing antigen-presenting cells.Science immunology · 2021Article
- TCR Recognition of Peptide-MHC-I: Rule Makers and Breakers.International journal of molecular sciences · 2020Review
- Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen.Nature communications · 2020Article
- Massively parallel interrogation and mining of natively paired human TCRαβ repertoires.Nature biotechnology · 2020Article
- Article
- Modeling and Viewing T Cell Receptors Using TCRmodel and TCR3d.Methods in molecular biology (Clifton, N.J.) · 2020Article
- Article
- Human cytomegalovirus-specific T-cell receptor engineered for high affinity and soluble expression using mammalian cell display.The Journal of biological chemistry · 2019Article
- TCRmodel: high resolution modeling of T cell receptors from sequence.Nucleic acids research · 2018Article
- Major TCR Repertoire Perturbation by Immunodominant HLA-BFrontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Cytomegalovirus (CMV) is a ubiquitous and persistent human pathogen that is kept in check by CD8(+) cytotoxic T lymphocytes. Individuals expressing the major histocompatibility complex (MHC) class I molecule HLA-A2 produce cytotoxic T lymphocytes bearing T cell receptors (TCRs) that recognize the immunodominant CMV epitope NLVPMVATV (NLV). The NLV-specific T cell repertoire is characterized by a high prevalence of TCRs that are frequently observed in multiple unrelated individuals. These public TCRs feature identical, or nearly identical, complementarity-determining region 3α (CDR3α) and/or CDR3β sequences. The TCRs may express public CDR3α motifs alone, public CDR3β motifs alone, or dual public CDR3αβ motifs. In addition, the same public CDR3α motif may pair with different CDR3β motifs (and the reverse), giving rise to highly diverse NLV-specific TCR repertoires. To investigate the structural underpinnings of this clonal diversity, we determined crystal structures of two public TCRs (C7 and C25) in complex with NLV·HLA-A2. These TCRs utilize completely different CDR3α and CDR3β motifs that, in addition, can associate with multiple variable α and variable β regions in NLV-specific T cell repertoires. The C7·NLV·HLA-A2 and C25·NLV·HLA-A2 complexes exhibit divergent TCR footprints on peptide-MHC such that C25 is more focused on the central portion of the NLV peptide than is C7. These structures combined with molecular modeling show how the public CDR3α motif of C25 may associate with different variable α regions and how the public CDR3α motif of C7 may pair with different CDR3β motifs. This interchangeability of TCR V regions and CDR3 motifs permits multiple structural solutions to binding an identical peptide-MHC ligand and thereby the generation of a clonally diverse public T cell response to CMV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.